

The LDN Book Volume Two

The Latest Research on How Low Dose Naltrexone Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and More

Linda Elsegood

Health & Wellness

\$27.99 USD • \$39.95 CAD • £22.50 GBP

Paperback • 6 × 9 • 288 pages

Black-and-white illustrations throughout

ISBN 978-1-60358-990-1

On-Sale Date: October 9, 2020

Media contact:

cbutt@chelseagreen.com

US event contact:

jstewart@chelseagreen.com



A comprehensive examination of LOW DOSE NALTREXONE—a little-known drug with big potential

A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is one not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike have found, low dose naltrexone (LDN) boasts this remarkable combination.


LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments.

Expanding on the information presented *The LDN Book Volume 1*—which showcased LDN's efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue—Volume 2 highlights the latest clinical trials, case studies, and research on LDN. More than a dozen medical professionals explain how they are using LDN to help patients suffering from chronic pain, Parkinson's disease, dermatologic conditions, traumatic brain injury, Lyme disease, and more.

The LDN Book Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.

To request a review copy or author interview, please contact: Christina Butt (802) 295-6300 ext. 127, or cbutt@chelseagreen.com

Author Availability: United Kingdom, or by phone or arrangement



Linda Elsegood is the founder of the LDN Research Trust based in the UK. Diagnosed with MS in 2000, she started LDN therapy in 2003, and now has a better quality of life and hope for the future. Through the Trust, she has connected thousands of patients, doctors, and pharmacists around the world with information, articles, and patient stories about LDN, and helps organize conferences, seminars, and The LDN Radio Show.

Chelsea Green Publishing is an employee-owned global publishing house with offices in the UK and US, and a leading publisher of books on the politics and practice of sustainable living. Founded in 1984, our books share new ideas on organic farming and gardening, alternative agriculture, green and renewable energy, environmental stewardship and activism, sustainable economy, health and wellness, politics and public policy, and more. Find out more at chelseagreen.com.